The objective of this work is to compare blood loss during primary knee arthroplasty with the use of intravenous and intraarticular (IV + IA) tranexamic acid intraarticular (IA) tranexamic acid alone. This is a randomized, double-blind clinical trial. Patients with indication for primary total knee arthroplasty were recruited in a specialized clinic, where they were operated by the same surgeon, always using the same surgical technique. Thirty patients were allocated in the IV + IA tranexamic acid group and 30 patients in the IA tranexamic acid group, according to randomization. Blood loss was compared through hemoglobin, hematocrit, drain volume, and blood loss estimation (Gross and Nadler calculus). After collection, data from 40 patients were analyzed, 22 in the IA group and 18 in the IV + IA group. There were 20 losses due to collection error. Between groups IA and IV + IA, there were no significant differences in 24 hours between hemoglobin levels (10.56 vs. 10.65 g/dL; F = 0.63, = 0.429), erythrocyte (3.63 vs. 3.73 million/mm ; F = 0.90, = 0.346); hematocrit (32.14 vs. 32.60%; F = 1.39, = 0.240); drainage volume (197.0 vs. 173.6 mL; F = 3.38 = 0.069); and estimated blood loss (1,002.5 vs. 980.1; F = 0.09, = 0.770). The same occurred in comparisons conducted after 48 hours postoperatively. Time was a significant factor for the change of all outcome variables. However, the treatment did not modify the effect of time on these outcomes. No individual presented any thromboembolic event during the work period. The use of IV + IA tranexamic acid showed no advantage in reducing blood loss when compared to the use of IA tranexamic acid alone in primary knee arthroplasties. This technique proved to be safe, since no thromboembolic event occurred during the development of the work.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212634 | PMC |
http://dx.doi.org/10.1055/s-0042-1757958 | DOI Listing |
Lung
January 2025
Department of Emergency Medicine, Aarupadai Veedu Medical College and Hospital, Vinayaka Missions Research Foundation, Puducherry, India.
Background: Hemoptysis, the expectoration of blood from the lower respiratory tract, varies in severity and necessitates effective management to mitigate morbidity. Traditional treatments include bronchial artery embolization and pharmacological approaches. Tranexamic acid (TXA), an antifibrinolytic agent known for its efficacy in reducing bleeding during surgery and trauma, is being explored for its efficacy in treating Hemoptysis via both intravenous and inhalational routes.
View Article and Find Full Text PDFBMC Med Genomics
January 2025
Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Chongqing Medical University, Chongqing, 400016, China.
Background: Clinical and epidemiological analyses have found an association between coronavirus disease 2019 (COVID-19) and knee osteoarthritis (KOA). Infection with COVID-19 may increase the risk of developing KOA.
Objectives: This study aimed to investigate the potential causal relationship between COVID-19 and KOA using Mendelian randomization (MR) and to explore the underlying mechanisms through a systematic bioinformatics approach.
JAMA
January 2025
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
JAMA
January 2025
Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.
Arch Orthop Trauma Surg
December 2024
Duke University Health System, Durham, USA.
Background: Jehovah's Witness patients refuse blood transfusion because of their religious beliefs making total hip arthroplasty (THA) challenging. This study aims to determine the safety of THA in Jehovah's Witness patients using standard perioperative protocols as well as evaluate the effectiveness of tranexamic acid (TXA) in controlling blood loss.
Methods: Databases from two tertiary academic centers were queried from 2003 to 2021 to identify THA patients.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!